[go: up one dir, main page]

CL2017001840A1 - Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas. - Google Patents

Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.

Info

Publication number
CL2017001840A1
CL2017001840A1 CL2017001840A CL2017001840A CL2017001840A1 CL 2017001840 A1 CL2017001840 A1 CL 2017001840A1 CL 2017001840 A CL2017001840 A CL 2017001840A CL 2017001840 A CL2017001840 A CL 2017001840A CL 2017001840 A1 CL2017001840 A1 CL 2017001840A1
Authority
CL
Chile
Prior art keywords
methods
high purity
pharmaceutical formulations
preparing
purity cangrelor
Prior art date
Application number
CL2017001840A
Other languages
English (en)
Inventor
Panna Dutta
Far Adel Rafai
Min Ding
Rajeshwar Motheram
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55537309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2017001840A1 publication Critical patent/CL2017001840A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A CANGRELOR DE ALTA PUREZA, FORMULACIONES FARMACÉUTICAS QUE COMPRENDEN CANGRELOR DE ALTA PUREZA CORNO UN INGREDIENTE ACTIVO, MÉTODOS PARA PREPARAR DICHOS COMPUESTOS Y FORMULACIONES, Y MÉTODOS PARA USAR LAS FORMULACIONES FARMACÉUTICAS EN LA INHIBICIÓN DE LA ACTIVACIÓN Y AGREGACIÓN DE PLAQUETAS.</p>
CL2017001840A 2015-01-14 2017-07-14 Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas. CL2017001840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562103136P 2015-01-14 2015-01-14

Publications (1)

Publication Number Publication Date
CL2017001840A1 true CL2017001840A1 (es) 2017-12-29

Family

ID=55537309

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001840A CL2017001840A1 (es) 2015-01-14 2017-07-14 Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.

Country Status (13)

Country Link
US (4) US9295687B1 (es)
EP (1) EP3244900A4 (es)
KR (1) KR102440847B1 (es)
CN (2) CN107206014A (es)
BR (1) BR112017014996A2 (es)
CA (1) CA2971868C (es)
CL (1) CL2017001840A1 (es)
CO (1) CO2017006958A2 (es)
MA (1) MA41326A (es)
MX (1) MX391152B (es)
PE (2) PE20171246A1 (es)
RU (1) RU2733409C2 (es)
WO (1) WO2016114818A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200445T1 (hr) * 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
EP3244900A4 (en) * 2015-01-14 2018-05-30 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
KR102768341B1 (ko) 2017-06-23 2025-02-18 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法
CN109781920B (zh) * 2017-11-15 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种坎格雷洛有关物质的hplc检测方法
CN109912674A (zh) 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
US20220040100A1 (en) * 2020-06-25 2022-02-10 RK Pharma Solutions LLC Stable Acyclovir Sodium Parenteral Formulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108425T3 (es) 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
GB9813646D0 (en) * 1998-06-24 1998-08-26 Ciba Geigy Ag Organic compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
JP4272991B2 (ja) 2001-09-21 2009-06-03 大日本住友製薬株式会社 凍結乾燥製剤
KR100970528B1 (ko) 2002-02-22 2010-07-16 쉐링 코포레이션 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120184504A1 (en) * 2009-10-02 2012-07-19 Strony John T "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis"
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
HRP20200445T1 (hr) * 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
WO2013103567A2 (en) * 2012-01-04 2013-07-11 The Medicines Company Methods of blocking platelet activation during extracorporeal circulation using cangrelor
CN103860459A (zh) * 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
EP3244900A4 (en) * 2015-01-14 2018-05-30 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Also Published As

Publication number Publication date
MX2017009289A (es) 2017-10-11
RU2017127531A (ru) 2019-02-14
MA41326A (fr) 2021-04-28
WO2016114818A1 (en) 2016-07-21
RU2017127531A3 (es) 2019-02-14
CO2017006958A2 (es) 2017-11-30
CA2971868C (en) 2023-04-04
KR20170103848A (ko) 2017-09-13
US9439921B2 (en) 2016-09-13
RU2733409C2 (ru) 2020-10-01
CA2971868A1 (en) 2016-07-21
CN107206014A (zh) 2017-09-26
MX391152B (es) 2025-03-21
CN115990138A (zh) 2023-04-21
US20160199400A1 (en) 2016-07-14
PE20221170A1 (es) 2022-07-25
US9295687B1 (en) 2016-03-29
US20170304345A1 (en) 2017-10-26
PE20171246A1 (es) 2017-08-24
US9700575B2 (en) 2017-07-11
US10039780B2 (en) 2018-08-07
BR112017014996A2 (pt) 2018-03-20
EP3244900A4 (en) 2018-05-30
EP3244900A1 (en) 2017-11-22
KR102440847B1 (ko) 2022-09-06
US20160296549A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
CL2017001675A1 (es) Derivados de quinazolina utilizados para tratar el vih
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
ECSP17069696A (es) Compuestos novedosos
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
CL2017002229A1 (es) Inhibidores de bace1.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
CO2019000083A2 (es) Composiciones farmacéuticas
GT201400115A (es) Combinación farmacéutica antineurítica y composición
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
UY36958A (es) Compuestos para administración intracelular